Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Apple Turns 50: From Garage Startup to AI Crossroads 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
 - EconoTimes)
NEW ORLEANS, Dec. 16, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until January 17, 2017 to file lead plaintiff applications in a securities class action lawsuit against Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), if they purchased the Company’s securities between February 10, 2014 and November 9, 2016, inclusive (the “Class Period”). The action is pending in United States District Court, Southern District of New York.
What You May Do
If you purchased securities of Alexion and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by January 17, 2017.
About the Lawsuit
Alexion and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) Alexion employed improper sales practices with respect to its product Soliris; (ii) that the Company’s revenues from Soliris sales were unlikely to be sustainable; and (iii) as a result of the foregoing, Alexion’s public statements were materially false and misleading at all relevant times.
Additionally, on December 12, 2016, Alexion announced the unscheduled departure of CEO David Hallal and CFO Vikas Sinha, who both resigned effective immediately.
On this news, the price of Alexion’s shares again plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
